Instalab
logoInstalab

Alpha-1 Antitrypsin

Blood Test
Check for an inherited cause of emphysema and liver scarring that routine blood panels can miss.
4.9 (4,678 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Alpha-1 Antitrypsin test?

This test is most useful if any of these apply to you.

Living With COPD or Persistent Breathing Trouble
Testing can identify a treatable contributor to lung disease, even if you're older or have a smoking history.
Related to Someone With the Deficiency
Your family history makes testing useful, but genetic testing is needed because a protein level alone can miss carriers.
Dealing With Unexplained Liver Problems
An inherited protein disorder can contribute to liver injury, sometimes alongside another known cause.
Following Up on a Low Alpha-1 Protein Band
A low band on serum protein electrophoresis is a reason to measure this protein directly and investigate the cause.

About Alpha-1 Antitrypsin

Emphysema and unexplained liver disease can have the same inherited cause. Alpha-1 antitrypsin deficiency reduces the supply of a protein that protects lung tissue, and some gene variants also cause that protein to accumulate inside the liver. A low blood level can be the first clue. Establishing the inherited cause requires protein typing or genetic testing.

This is an established test for investigating deficiency. The condition still often goes unrecognized, with several years commonly passing between the first symptoms and diagnosis. A higher result has a different interpretation: infection, inflammation and estrogen can all increase the amount in your blood. Its use as a general predictor of future illness remains exploratory.

What the Number Reflects

AAT is made mainly in your liver and released into your bloodstream. It blocks neutrophil elastase, an enzyme that breaks down proteins. Neutrophils are white blood cells that release this enzyme during an immune response. AAT limits damage to surrounding tissue, including the elastic fibers that help your lungs expand and recoil.

This test measures the total concentration of AAT in serum from a blood draw. Serum is the liquid remaining after blood clots. The standard quantitative method uses antibodies and scattered light to measure the protein. The method is called nephelometry. It measures the amount present without directly measuring how well that protein blocks enzymes.

You inherit one copy of the SERPINA1 gene from each parent. The common M version usually produces AAT that works normally. The S and Z versions can reduce the circulating supply, with Z responsible for most severe inherited deficiency. Z protein folds incorrectly and can collect inside liver cells, leaving less available to reach the lungs.

The gene variants matter beyond their effect on the number. Some rare variants produce little or no protein without causing the same buildup in the liver. Others produce protein that is present but works poorly. Inflammation, hormone exposure, protein loss and severe impairment of liver production can also change the measured concentration.

Emphysema and Other Lung Disease

COPD is a group of long-term lung conditions that obstruct airflow. Emphysema destroys the walls of the lung's air sacs and is a major consequence of severe AAT deficiency. When enzyme-blocking protection is inadequate, tissue damage can accumulate. Smoking greatly accelerates this process.

Early emphysema is a familiar presentation, but age and smoking history don't reliably identify everyone with the condition. Deficiency can also accompany bronchiectasis. In this condition, airways become permanently widened and are prone to repeated infections. Some people initially receive an asthma diagnosis, particularly when persistent airflow obstruction is part of the picture.

The amount of protein in your blood helps establish deficiency, but it doesn't measure how much lung tissue has already been lost. People with the same severe genotype can have very different lung function.

Liver Scarring and Liver Cancer

The liver injury has a different cause from the lung injury. Certain abnormal proteins, especially Z protein, collect inside liver cells and can damage them. This can lead to scarring, cirrhosis and an increased risk of primary liver cancer. Liver disease can begin in childhood or develop later in adulthood.

A low circulating concentration doesn't show how much protein has accumulated inside the liver or how much scarring is present. The inherited variants and other liver risks matter. Liver enzymes can also remain unremarkable despite fibrosis, so a reassuring blood panel doesn't always exclude scarring.

Another explanation for liver disease can coexist with AAT deficiency. In a US study of about 126,000 veterans with cirrhosis, only about a third had been tested. Nearly 95% of those classified as having severe deficiency also had another recorded cause of liver disease. The study used low protein levels or qualifying genetic results to identify severe deficiency, and genetic confirmation was incomplete.

Separate research assays measure chains of abnormal Z protein called polymers. These measure a particular form of AAT, whereas this test measures total AAT concentration. Higher circulating polymer levels have been associated with liver scarring. In a European study, the association with subsequent serious outcomes became uncertain after accounting for age. Those findings don't establish total serum AAT as a marker of liver disease progression.

Long-Term Outcomes

A Swedish study compared 2,286 people with a recorded diagnosis of AAT deficiency with about 22,000 matched people from the general population. During follow-up, mortality was about 3.6 times higher in adjusted analyses.

OutcomeFinding in the Diagnosed Swedish Group
Death from liver diseaseAbout 23 times higher in adjusted analyses
Death from respiratory diseaseAbout 12 times higher in adjusted analyses
Death from cardiovascular diseaseNearly twice as high in adjusted analyses

These estimates describe people who received a diagnosis in clinical care, many with existing illness. The study lacked detailed genotype information. Its estimate that about one in five remained alive without lung disease or cirrhosis around 20 years after diagnosis should not be applied to an otherwise healthy person with a newly identified variant.

A separate Swedish study followed 377 people with severe deficiency identified through screening. Never-smokers had better lung function and survival than people who had smoked. Because this was observational, it doesn't establish how much screening itself changed outcomes. It does show why smoking history matters when interpreting prognosis.

Heart Disease and Inflammation Research

The cardiovascular findings depend on what researchers study. A pooled analysis involving about 24,000 people with deficiency or associated genotypes found about 22% lower odds of ischemic heart disease. This is heart disease caused by inadequate blood supply, usually from narrowed coronary arteries. The studies were observational, their results varied, and one study supplied about 80% of the deficiency group.

That finding concerns deficiency status and genetic background, not the effect of lowering a routine blood result. It also concerns a different outcome and population from the cardiovascular mortality analysis in Sweden. These findings don't establish that inherited deficiency protects you from cardiovascular disease.

Research on higher concentrations has a separate limitation. One study linked estimated AAT levels with future heart failure, pneumonia, liver disease and death. Researchers trained a model using directly measured serum proteins in 626 people, then estimated AAT from other blood signals in nearly 12,000 people with follow-up data. The outcome analysis therefore used modeled concentrations, rather than this routine serum measurement.

Those associations support further study of inflammatory proteins. They haven't established a treatment target for high AAT or shown that adding serial AAT testing improves cardiovascular prevention.

High Levels and Inflammation

AAT is an acute-phase protein. Its production increases during inflammation, including infection, injury and surgery. The size of the increase varies with the inflammatory response and the gene variants you carry.

In a study of 160 people, those hospitalized with community-acquired pneumonia had concentrations about 1.6 times those of healthy controls. That study measured plasma AAT with a research antibody assay, a related measurement that isn't directly interchangeable with routine serum nephelometry. Higher concentrations were associated with worse pneumonia severity scores, but the study didn't establish that the test predicted death or improved treatment decisions.

A separate cross-sectional study of serum AAT found higher concentrations in several inflammatory lung conditions, including COPD, cystic fibrosis and some diseases involving lung scarring. These group differences don't make a high result specific to any one disease. CRP can help show whether inflammation is present, but neither marker identifies its source.

Less Common Associations

AAT deficiency is also associated with necrotizing panniculitis, which causes painful inflammation and breakdown of fat beneath the skin. Another recognized association is granulomatosis with polyangiitis, which inflames small blood vessels and can affect the lungs, kidneys and upper airways. These are specific conditions; the association doesn't extend equally to every rash or form of blood vessel inflammation.

When Results Can Be Misleading

  • Inflammation and infection: A temporary rise can conceal an inherited reduction, especially in people carrying one deficiency variant. A reassuring concentration during illness doesn't exclude a variant.
  • Pregnancy and estrogen: Pregnancy, estrogen-containing contraceptives and hormone therapy can raise the concentration.
  • Smoking: Active and passive smoke exposure have been associated with higher serum AAT. This inflammatory rise can occur while smoke is increasing lung injury.
  • Reduced production or protein loss: Severe liver dysfunction, substantial protein loss through the kidneys, and protein-losing intestinal disease can lower AAT without an inherited deficiency.
  • Protein amount versus function: Some variants impair the protein's activity without a large reduction in its concentration. Rare variants can also resemble the usual M protein on phenotype testing.
  • Recent replacement therapy: Donated AAT raises the measured concentration and can affect protein typing. Interpretation depends on the timing of the infusion; treatment doesn't change your inherited DNA.
  • Analytical interference: Fat particles and other sources of cloudiness can interfere with light-scattering measurements. Calibration and assay differences can also affect comparisons between laboratories.

What Changes Over Time

Your inherited variants stay the same, while the circulating protein concentration can change with inflammation, hormones, protein loss and treatment. A change in this number alone doesn't establish that emphysema or liver scarring has improved or worsened. Once deficiency is characterized, lung function and liver assessment provide the information needed to follow organ health.

What Moves This Biomarker

Evidence-backed interventions that affect your Alpha-1 Antitrypsin level

↑ Increase
Receive prescribed intravenous alpha-1 antitrypsin augmentation therapy
Weekly infusions of purified donor protein raise serum AAT and restore enzyme-blocking protection in adults with severe inherited deficiency and emphysema. The standard approved dose is 60 mg/kg weekly. In a pooled analysis of two randomized trials, loss of lung density on CT was about a third slower with treatment. Randomized trials haven't established a survival benefit or a consistent improvement in breathing-test results. Infusions don't treat the abnormal protein accumulating inside liver cells.
MedicationStrong Evidence
↓ Decrease
Receive fazirsiran in a clinical trial for ZZ deficiency-associated liver disease
Fazirsiran suppresses production of abnormal Z protein, reducing its concentration in blood and its accumulation in the liver. A randomized phase 2 trial showed large reductions in serum Z-AAT and liver deposits. The blood endpoint used a Z-specific assay; in people with two Z copies, Z-AAT is the form produced by their liver. Reducing this protein may benefit liver disease, but it also lowers an already limited circulating supply. Prevention of liver failure and long-term lung safety remain unproven.
MedicationStrong Evidence
↑ Increase
Undergo liver transplantation for advanced deficiency-associated liver disease
A donor liver with normal AAT production replaces the diseased liver and restores the circulating protein supply. This treats advanced liver disease as well as the liver's failure to release enough AAT. It doesn't reverse established emphysema and isn't a treatment for an isolated low blood result.
ProcedureStrong Evidence

Frequently Asked Questions

References

33 studies
  1. Mayo Clinic LaboratoriesMayo Clinic Laboratories2026
  2. Borja Ruiz-duque, Lucía Bañuls, Rocío Reinoso-arija, Laura Carrasco-hernández, Candela Caballero-eraso, Francisco Dasí, José Luís López-camposJournal of Clinical Medicine2021
  3. Robert a. Sandhaus, Gerard Turino, Mark L. Brantly, N. Gerard Mcelvaney, James K. Stoller, Charlie StrangeChronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation2016
  4. Paulo Henrique Ramos Feitosa, Maria Vera Cruz De Oliveira Castellano, Claudia Henrique Da Costa, Amanda Da Rocha Oliveira Cardoso, Luiz Fernando Ferreira Pereira, Frederico Leon Arrabal Fernandes, Fábio Marcelo Costa, Manuela Brisot Felisbino, Alina Faria França De Oliveira, Jose R. Jardim, Marc MiravitllesJornal Brasileiro De Pneumologia2024
  5. James K. Stoller, Vera Hupertz, Loutfi S. AboussouanGenereviews2023

Alpha-1 Antitrypsin Test

$55
FSA/HSA eligible
No Rx needed
HIPAA compliant